Nephrosclerosis - arteriolar
Methodology & AI Transparency ⓘ
Nephrosclerosis - arteriolar Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as I12.9, Nephrosclerosis - arteriolar falls under Blood Pressure management, where segmental arterial Doppler in Nephrosclerosis - arteriolar (I12.9: waveforms) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry I12.9: Nephrosclerosis - arteriolar is managed within Blood Pressure.
- 3 Typical cash cost range: Differential triage of Nephrosclerosis - arteriolar (I12.9) utilizes segmental arterial Doppler in Nephrosclerosis - arteriolar (I12.9: waveforms).
- 4 Top reported side effects / signs: Follow-up benchmark in Nephrosclerosis - arteriolar: maintaining Ankle-Brachial Index (ABI) [Nephrosclerosis - arteriolar I12.9] within 1.00 – 1.30 (I12.9).
Ask our AI Specialists anything about Nephrosclerosis - arteriolar
What Is Nephrosclerosis - arteriolar?
Designated in federal medical registries as I12.9, Nephrosclerosis - arteriolar falls under Blood Pressure management, where segmental arterial Doppler in Nephrosclerosis - arteriolar (I12.9: waveforms) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Nephrosclerosis - arteriolar (I12.9) features elevated systemic vascular in Nephrosclerosis - arteriolar (I12.9: resistance). therapeutic stabilization in blood pressure is verified against Serum Creatinine & in Nephrosclerosis - arteriolar (I12.9: Potassium).
Common Symptoms & Clinical Signs
- • Presentation of Nephrosclerosis - arteriolar (I12.9): localized extremity swelling, in Nephrosclerosis - arteriolar (I12.9: warmth, or venous)
- • Secondary Nephrosclerosis - arteriolar clinical sign: cold distal extremities in Nephrosclerosis - arteriolar (I12.9: or diminished peripheral)
- • Symptom flares in Nephrosclerosis - arteriolar correlating with Ankle-Brachial Index (ABI) [Nephrosclerosis - arteriolar I12.9] deviation outside 1.00 – 1.30 (I12.9)
- • Functional blood pressure impact requiring segmental arterial Doppler in Nephrosclerosis - arteriolar (I12.9: waveforms) evaluation (I12.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Nephrosclerosis - arteriolar Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I12.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Nephrosclerosis - arteriolar I12.9] | 1.00 – 1.30 (I12.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Nephrosclerosis - arteriolar (I12.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I12.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Nephrosclerosis - arteriolar I12.9] | < 15 mg/g (I12.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nephrosclerosis - arteriolar
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Hydralazine Hydrochloride and Isosorbide Dinitrate Isosorbide Dinitrate and Hydralazine Hydrochloride, Bidil • RxCUI 905377 | Nitrate Vasodilator | 92% | $4.3452 | $ 184.48 /mo |
| Hims Hair Regrowth Treatment (Minoxidil) Hims Hair Regrowth Treatment • RxCUI 645146 | Arteriolar Vasodilator | 80% | $0.1971 | $ 22.69 /mo |
| Minoxidil Topical Solution, 5% (Minoxidil Solution) Minoxidil Topical Solution, 5% • RxCUI 311724 | Arteriolar Vasodilator | 88% | $0.2705 | $ 27.98 /mo |
| Hair Champu (Minoxidil) Hair Champu • RxCUI 197986-B87022007 | Arteriolar Vasodilator | 79% | $0.1971 | $ 22.69 /mo |
| Stay Minoxidil Hair Regrowth Treatment (Minoxidil 5%) Stay Minoxidil Hair Regrowth Treatment • RxCUI RXN-B87210351 | Arteriolar Vasodilator | 91% | $0.1971 | $ 22.69 /mo |
| Hair Serum (Minoxidil 5%) Hair Serum • RxCUI 311724-B83804003 | Arteriolar Vasodilator | 74% | $0.1971 | $ 22.69 /mo |
| Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Keeps Minoxidil Topical Solution, 5% • RxCUI 311724-B71713102 | Arteriolar Vasodilator | 90% | $0.2810 | $ 28.73 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nephrosclerosis - arteriolar)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety Profile of Bremelanotide Across the Clinical Development: What a 1,247-Participant Study Found Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of heart and blood vessel disease, and blood pressure should be well controlled during treatment. Journal of women's health (2002) • 2022-02-15 • Phase III Randomized Trial | N = 1,247 | 96/100 | PMID 35147466 ↗ |
| New Insights on Safety and real-world benefits of ubrogepant in participants with major heart and: What a 311-Participant Study Found The safety and real-world benefits of ubrogepant for the acute treatment of a single migraine attack did not differ by the presence of major heart and blood vessel risk factors. Cephalalgia : an international journal of headache • 2021-08-15 • Phase III Randomized Trial | N = 311 | 93/100 | PMID 33874756 ↗ |
| New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2021-10-15 • Phase III Randomized Trial | N = 892 | 93/100 | PMID 33340238 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III randomized clinical trial of real-world benefits and safety of AEs occurred in 11.24% of the AML + CC group and 5.62% of the AML group (p = 0.1773). Scientific reports • 2024-10-03 • Phase III Randomized Trial | N = 174 | 88/100 | PMID 39358448 ↗ |
| New Insights on A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating: What a 691-Participant Study Found The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. American journal of ophthalmology • 2024-08-15 • Phase III Randomized Trial | N = 691 | 87/100 | PMID 38499140 ↗ |
Nephrosclerosis - arteriolar Patient Community & “People Like Me” Threads
Filter Nephrosclerosis - arteriolar community threads and patient logs by age, biological sex, dosage, and treatment duration.